

# Measurement of Glutathionylated Haemoglobin by MALDI-ToF Mass Spectrometry as a Biomarker of Oxidative Stress in Heavy Smokers and in Occupational Obese Subjects

Federico Maria Rubino<sup>1\*</sup>, Cinzia Della Noce<sup>2</sup>, Luisella Vigna<sup>3</sup>, Rachele De Giuseppe<sup>4</sup>,  
Cristina Novembrino<sup>5</sup>, Federica de Liso<sup>5</sup>, Rita Maiavacca<sup>5</sup>, Lorenzo Patrini<sup>3</sup>, Luciano Riboldi<sup>3</sup>,  
Fabrizia Bamonti<sup>4</sup>

<sup>1</sup>Laboratorio di Tossicologia e Metabonomica Analitica (LaTMA), Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy

<sup>2</sup>Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Dipartimento CardioToracico e Vascolare, Ospedale Niguarda Ca' Granda, Milano, Italy

<sup>3</sup>Dipartimento di Medicina Preventiva, U.O. Medicina del Lavoro, "Clinica del Lavoro L Devoto", Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

<sup>4</sup>Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Unità Operativa di Ematologia e CTMO, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico via F. Sforza 35, Milano, Italy

<sup>5</sup>Laboratorio Centrale di Analisi Chimico Cliniche e Microbiologia, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, via F. Sforza 35, Milano, Italy  
Email: \*federico.rubino@unimi.it

Received July 10, 2013; revised August 16, 2013; accepted September 7, 2013

Copyright © 2013 Federico Maria Rubino *et al.* This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

Glutathionyl-haemoglobin (Hb-SSG) is a minor form of haemoglobin characterized by the presence of a disulfide bond between the  $\beta$ -93 cysteine residue and the thiol group of glutathione. Hb-SSG is naturally present in the erythrocytes at levels comparable to those of glycated haemoglobin and can be measured by MALDI mass spectrometry on very small samples of erythrocytes from peripheral blood. Since Hb-SSG has been recognized as a sensitive biomarker of oxidative stress in several degenerative diseases (diabetes, hyperlipidemia, kidney disease) and in healthy workers exposed to glutathione-depleting toxic agents such as butadiene, we have measured for the first time the levels of Hb-SSG in two groups: healthy heavy cigarette smokers and overweight-obese. For both classes of subjects, the measured levels ( $6.4\% \pm 1.7\%$ ,  $n = 30$  for smokers;  $3.0\% \pm 0.8\%$ ,  $n = 20$  for overweight-obese) are in the upper 97<sup>th</sup> percentile of those measured in the Italian general population. Levels in smokers show a small, yet statistically significant dependence on the level of smoking addiction ( $>20$  cig./day vs.  $\leq 20$  cig./day:  $7.0\% \pm 1.4\%$  vs.  $5.7\% \pm 1.1\%$ ;  $p < 0.05$ ). This biomarker thus adds to those presently available to rationally assess the extent of biological damage caused by tobacco smoking.

**Keywords:** Biomarker; Glutathionyl-Haemoglobin; Oxidative Stress; Erythrocyte; Mass Spectrometry

## 1. Introduction

Tobacco smoking is a long known major cause of morbidity and premature death, mainly due to cardiovascular disease and lung cancer. Among the toxic effects of inhalation of the combustion products of tobacco, a main one is the induction of local and systemic oxidative stress. This condition occurs when the excessive production of, or exposure to, reactive chemical substances (e.g. metal

ions, unsaturated aldehydes, quinones) overwhelms the level of natural defence mechanisms, (e.g. free radical quenchers, antioxidant enzymes, electrophile scavengers). As a consequence, key enzymes can be inactivated and cellular functions impaired to the point that diseases such as atherosclerosis and cancer can be triggered [1].

Overweight or obesity is a common condition in the population of the "western" world and can lead to long-term health impairment and risk of myocardial infarction, brain stroke and other life-threatening complications [2].

\*Corresponding author.

One condition which may hamper weight loss notwithstanding interventions on diet and physical exercise is possibly an underlying condition of systemic oxidative stress [3-5].

It has been very recently claimed that several components of the atherosclerotic plaque are themselves able to generate reactive oxygen species thus sustaining chronic oxidative damage to biological structures [6].


The reversible oxidation of the thiol function of cysteine into the disulfide plays a key role as a buffer of oxidation. The pool of cysteine-containing natural antioxidants collectively is referred to as the glutathione metaboloma scavenges noxious agents through the formation of the respective thioethers, while the transcription and the activity of detoxifying enzymes are modulated through the action of molecular switches based on the dynamic formation and dissociation of conformation-crucial disulfide bonds in the catalytic or allosteric domains of key proteins.

Smoking has been recognized as one of the major source of an enhanced oxidation of the circulating pools of glutathione and cysteine to the corresponding disulfides. The measurement of the concentrations of thiol and disulfide forms of plasma and erythrocyte thiols has been employed to calculate the electrochemical potential as a synthetic bioindicator of the redox state of tissues of non-smokers and smoking subjects [7].

Mixed disulfides of soluble thiols such as glutathione and cysteine with proteins also contribute to the pool of oxidized thiols. In particular, glutathionyl haemoglobin (HbSSG) is the mixed disulfide generated by reaction of erythrocyte haemoglobin with glutathione disulfide [8] (**Scheme 1(a)**) or with the sulphinic acid derivative of glutathione [9] (**Scheme 1(b)**) to yield a disulfide bond between the thiol group of glutathione and that of the side chain of the  $\beta$ -93 residue of cysteine.

This form of Hb is naturally present in erythrocytes as a fraction of total haemoglobin and is thus a viable candidate as an innovative biomarker of cellular oxidative stress [10] (both *in vitro*; [11] and *in vivo*, see **Table 1**) as well as glycated Hb which is a marker of glycemic status. HbSSG has been measured in micro-samples of peripheral blood with several instrumental techniques among which ion-exchange chromatography [12] and mass spectrometry [13,14].

HbSSG levels have been so far measured in the control population and in selected patient populations in a few



**Scheme 1. Mechanisms for production of S-glutathionylated haemoglobin in oxidatively stressed erythrocytes.**

countries differing from one another for ethnicity of population, for lifestyle and for the ease of access to high-quality health service. A total number of subjects approaching one thousand have been examined. The results of the studies published in the literature are collected in **Table 1** (see references [12-23] therein).

As a biomarker of oxidative stress, HbSSG has been found to increase in a number of different conditions, including pathological states such as uncontrolled diabetes, nephropathy, dislipidemia, Down's syndrome and Friedreich's ataxia. It has also been found that clinical interventions such as haemodialysis in nephropathic patients and administration of dietary supplements in diabetic and dislipemic patients are able to lower its concentration, while patients under chronic treatment with antiepileptic drugs show increased levels. HbSSG is also increased in a dose-dependent way in healthy subjects who are occupationally exposed to butadiene in chemical plants.

To investigate whether HbSSG can add up to the array of useful biomarkers for assessing the extent of oxidative stress in two conditions, smoking and obesity, which are common in the general population, we have measured for the first time the levels of HbSSG in a group of selected heavy smokers and in one of clinically obese patients.

## 2. Materials and Methods

### 2.1. Investigated Subjects

Thirty healthy (no signs of respiratory impairment) heavy smokers, defined as declaring to smoke >20 cig/day for at least 10 years, were randomly selected from the population of a study the main results of which were reported previously [24,25]. Twenty otherwise healthy subjects, defined as obese on then basis of their Body Mass Index (BMI) exceeding the cut-off value of 25 were enrolled from our outpatient clinic [26].

The main characteristics of the fifty subjects are shown in **Table 2**. Blood samples were obtained upon enrolment and after an informed consent were signed by each, as part of their routine clinical assessment.

This study was conducted according to the Declaration of Helsinki guidelines for Research on Human Subjects and was approved by Human Ethic Committees of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Registration number: 1370).

### 2.2. Instrumentation

HbSSG was measured by Matrix-Assisted Laser-Desorption Time-of-Flight (MALDI-ToF) mass spectrometry, essentially following the method of Biroccio *et al.* (2005). Measurements were performed on an Autoflex III (Bruker Daltonics) instrument equipped with a 355 nm Smart Beam solid state Nd:YAG UV laser and operated according to the manufacturer's directions in the

linear positive ion mode at a calculated resolution of approximately 5000. External calibration of the  $m/z$  scale was accomplished with the manufacturer's custom protein mixture. Automated routines for the analysis of a large number of samples were established with the Flex Control™ software.

### 2.3. Measurement Techniques

For the measurement of HbSSG a 2 mL blood sample

was withdrawn (EDTA anticoagulant) and RBC were immediately separated by centrifugation, washed with isotonic NaCl solution and aliquoted in 0.1 mL portions of lysate which were immediately stored at  $-20^{\circ}\text{C}$  prior to analysis.

The MALDI matrix was composed of an acetonitrile-water 1:1 mixture saturated at room temperature with solid sinapinic acid (approximately 10 mg/mL) which was freshly prepared for each measurement session.

**Table 1. Levels of glutathionyl-haemoglobin measured in the control population and in selected patient populations in different countries.**

Cohort	country	N <sup>a</sup>	F <sup>b</sup>	age	GSSG (%)	Technique	details	Ref.
Normal population	Jap	20	10		3.7 ± 0.3	ESI-MS		[13] Naito, 1999
Normal population	I	20	10		8 ± 1.8	MALDI-ToF	age-matched	[15] Piemonte, 2001
Normal population	USA	9			1.21 ± 0.14	IEX; ESI-MS		[16] Al-Abed, 2001
Normal population	I	64	34	5.1 ± 2.3	2.65 ± 1.1	MALDI-ToF		[12] Pastore, 2003
Normal population	I	7			> 5.2	MALDI-ToF	101 M, 83 F	[14] Biroccio, 2005
Normal population	I	57			1.6 - 5.2	MALDI-ToF	102 M, 83 F	[14] Biroccio, 2005
Normal population	I	120			<0.5 (65.2%)	MALDI-ToF	103 M, 83 F	[14] Biroccio, 2005
Normal population	In	30		54 ± 6.7	4.85 ± 1.12	ESI		[17] Sampathkumar, 2005
Control group	In	15		49 ± 7.6	3.15 ± 1.99	ESI		[18] Mandal, 2007
Foresters	I	76		41 ± 9	2.1 ± 1.7	MALDI-ToF		[19] Primavera, 2008
Workers not exposed to butadiene	I	41		42 ± 7	6.3 ± 2.0	MALDI-ToF		[19] Primavera, 2008
Diabetes mellitus	Jap	10			10.2 ± 0.8	ESI	Basal value	[20] Naito, 2000
Diabetes mellitus	Jap	10			4.1 ± 0.4	ESI	After Vit. E	[20] Naito, 2000
Diabetes type 2	Jap	37	13		7.9 ± 0.5	ESI-MS		[21] Niwa, 2000
Diabetes mellitus	USA	20			2.26 ± 0.29	IEX; ESI-MS		[16] Al-Abed, 2001
Diabetes mellitus w/o microangiopathy	In	47		56 ± 6.8	8.69 ± 1.24	ESI		[17] Sampathkumar, 2005
Diabetes mellitus w/ microangiopathy	In	53		57 ± 8.4	10.94 ± 0.81	ESI		[17] Sampathkumar, 2005
Hyperlipemic subjects	Jap	17	11		8.1 ± 0.8	ESI		[21] Niwa, 2000
Haemodialysis patients	Jap	10			18.6 ± 0.9	ESI	Pre-dialysis	[13] Naito, 1999
Haemodialysis patients	Jap	10			20.8 ± 0.9	ESI	Post-dialysis	[13] Naito, 1999
Hemodialysis group	In	15		50.1 ± 8.5	4.69 ± 3.19	ESI		[18] Mandal, 2007
Peritoneal dialysis group	In	15		54.2 ± 7.1	9.99 ± 2.97	ESI		[18] Mandal, 2007
Transplant group	In	12		49.1 ± 6.8	7.63 ± 1.81	ESI		[18] Mandal, 2007
Heavy smokers	I	30		45.5 ± 8	6.4 ± 1.7%	MALDI-ToF		this study
Obese	I	20	15	49.8 ± 13.3	3.0 ± 0.7%	MALDI-ToF		this study
Chemical workers exposed to butadiene	I	41		34 ± 7	7.2 ± 2.8	MALDI-ToF		[19] Primavera, 2008
Epileptic patients (PHE-CBZ)	Yu	23			2-7	IEX		[22] Niketic, 1992
Friedreich's ataxia	I	14	9	13.9 ± 4.1	15 ± 1.5	MALDI-ToF		[15] Piemonte, 2001
Down's syndrome	I	46	26	6.7 ± 2.7	1.47 ± 0.6	MALDI-ToF		[12] Pastore, 2003
Carotid stenosis surgery patients	I	6		59 - 83	< 0.5	MALDI-ToF	No HbSSG	[23] Ghilardi, 2013
Carotid stenosis surgery patients	I	3		59 - 83	0.5 - 10	MALDI-ToF	Constant level	[23] Ghilardi, 2013
Carotid stenosis surgery patients	I	3		59 - 83	2 - 9	MALDI-ToF	Rise and fall	[23] Ghilardi, 2013

**Notes.** <sup>a</sup> total number of subjects investigated in the study; <sup>b</sup> number of female subjects. Abbreviations: ESI: electrospray ionization mass spectrometry; IEX: ion-exchange chromatography; MALDI-ToF: matrix-Assisted Laser Desorption Ionization – Time-of-Flight mass spectrometry.

**Table 2. Main characteristics of the examined subjects.**

smokers	N	Age <sup>a</sup>	Smoking (cig/day) <sup>a</sup>	>20 cig/day
M	15	46 (28 - 70)	24 (10 - 40)	5/15
F	15	45 (35 - 59)	23 (20 - 40)	6/15
total	30	45.5 ± 8 (28 - 70)	23.7 ± 6.7 (10 - 50)	11/30
obese				Body Mass Index <sup>a</sup>
M	5	53 (37 - 67)	None	34.5 (33.0 - 37.6)
F	15	44 (26 - 71)	3/15 current 4/15 former	32.9 (27.3 - 44.3)
total	20	51 (26 - 71)		

<sup>a</sup> median (min-Max).

For sample preparation one portion of frozen separated RBC was thawed and a 1:100 haemolysate was prepared. 10 microliters of the hemolysate were mixed to an equal volume of a matrix solution, thoroughly mixed and four 1-microliter portions from the same mixtures were applied each one in the centre of a different circular spot of a standard 384-sample ground steel target (Bruker MTP384 S/N 03229). Evaporation of the solvents was accomplished in the free air at room temperature. The manual preparation of one plate with approximately 250 spots (240 sample spots and a number of protein calibration samples) took approximately 2 hours. Sample plates were inserted into the mass spectrometer for analysis within 4 hours from preparation.

For analysis, desorption ionization of sample spots was accomplished by firing the laser beam according to an automated routine and accumulating valid spectra until a suitable signal-to-noise ratio was obtained. Analysis of an individual spot took approximately 2 - 3 min. Unattended analysis of the whole plate containing the samples of this study (approx. 250 spots) took approximately eight hours. After acquisition, MALDI spectra were analyzed off-site. Spectra annotation and manual integration was performed by a 'blind' operator with the FlexAnalysis™ software and compared to that obtained with the operator-independent routine.

Analysis and integration parameters are collected in **Table 3**. Results were exported to a custom Microsoft Excel® worksheet for further elaboration.

## 2.4. Statistical Elaboration

All calculations, statistical elaborations and graphics were performed in custom Microsoft Excel® worksheets. Statistical significance of differences was demonstrated by two-tailed *t*-test at a significance level of 5%.

## 3. Results

### 3.1. Method Establishment

Due to the large number of samples which need to be measured in clinically-oriented studies and to the necessity to perform an operator-independent unbiased measurement, all stages of the analytical process, start-

ing from sample preparation and deposition, laser firing and mass spectrometer focussing, automation of measurement and integration were the object of an optimization study and were modified with reference to the published method by Biroccio *et al.* [14].

### 3.2. Instrumental Routine Procedures.

To implement automated spectra processing with the FlexControl™ software, external calibration of the *m/z* scale was accomplished at the beginning of each measurement session with the manufacturer's custom protein mixture and internal calibration of the measured haemoglobin samples was accomplished in each measured sample by using the signals of doubly- and singly-protonated homozygous  $\alpha$ - and  $\beta$ -haemoglobin (*m/z* 7564.2; 7934.2; 15128.4 and 15867.5 respectively).

### 3.3. Sample Preparation and Measurement

Main modifications to the published procedure included using a single-layer of sinapinic acid matrix-sample mixture, in order (a) to achieve a faster sample preparation and deposition, (b) to avoid the formation of a "crusty" matrix lump, thus allowing to use a much lower laser power, which generates a lower contamination of the ion source and results in a lower laser consumption. The best compromise was reached by using a total number of 2500 shots in 50-shot groups, each fired in a different position of the sample shot, selected by the automated sample plate movement routine in the "random walk" mode. As for mass spectrometer focussing, using a very low Post-Ionization Extraction Delay (PIE) time proved beneficial especially in terms of resolution of the peak of protonated HbSSG from nearby "shoulders", thus allowing to appreciate abundances lower than 1%.

### 3.4. Analytical Performance

Following optimization of all parameters, analytical precision of each sample was calculated on the basis of four replicate measurements recorded on four different spot depositions and automatically measured within the same analytical run. For samples with HbSSG/HbSH

**Table 3. Parameters for the measurement of glutathionyl haemoglobin with the automated technique in the bruker autoflex instrument.**

AutoXecute method		
Laser:	Fuzzy control – Parent mode ON	Weight 1.00
	Use initial laser power on new laser spot	Initial laser power 35%
		Max laser power 45%
Evaluation:	Use masses from 5000 Da to 15000 Da for evaluation and processing.	
Accumulation:	Fuzzy control: OFF	Sum up: 2000 shots in in 100-shot steps
	Allow only 100 satisfactory shots per raster spot	
Movement:	Measure raster: spiral very small	
	Maximal allowed shot number at one raster position – Parent mode 100	
Processing:	DEFAULT	
MS/MS:	DEFAULT	
FlexAnalysis - Processing method		
Peak detection algorithm	Centroid	
Signal to noise threshold	6	
Relative intensity threshold	0	DEFAULT
Minimum intensity threshold	0	DEFAULT
Maximum number of peaks	50	
Peak width	10	
Height	80%	DEFAULT
Smoothing algorithm	Savitzky-Golay	
Width	5	
Cycles	3	
Baseline subtraction	TopHat	DEFAULT

ratios in the range of 3.5% - 11.7% was usually of 0.4% (<0.1% - 1.1%).

### 3.5. Reliability of Glutathionyl-Haemoglobin Measurement

Two possible causes of measurement bias were evaluated: (a) generation of HbSSG by RBC autoxidation after blood withdrawal, especially under conditions when separation of RBCs from whole blood had to be delayed by as long as 6 hours or strict temperature control at +4°C could not be warranted over the same time and (b) decomposition of HbSSG following sample storage.

To check whether HbSSG could be generated after blood sampling from the investigated subjects and prior to analysis, new aliquots of washed and packed RBCs of some control subjects coming from other similar studies, which had yielded no detectable levels of HbSSG, were re-analyzed for confirmation immediately after preparation and after being kept at ambient

temperature for 12 - 16 hours. None of the examined samples showed formation of HbSSG either in the first or in the second analytical run, thus out-ruling its artefact formation as a consequence of sample processing and storage.

To check whether HbSSG may decompose upon sample storage, washed and packed RBC samples with initial HbSSG levels between 2 and 8% coming from this and from other similar studies were prepared and re-analyzed along with the samples of the current study. HbSSG levels in washed and packed RBCs do not change significantly when samples are stored at -20 to -80°C for at least six months. These results, as a whole, demonstrate that measurement of HbSSG in RBC haemolysates by MALDI-ToF mass spectrometry is able to reliably detect event-related changes of 0.5 to 0.8% of absolute values.

The MALDI mass spectra of haemoglobin samples obtained from subjects with no detectable (upper panel) and high (lower panel) levels of haemoglobin glutathionylation are shown in **Figure 1**.

The upper spectrum, with no detectable HbSSG signal (subject not included in this study), is only shown to the purpose of exemplifying the detection level of the employed analytical technique. The subject yielding the lower spectrum exemplifies the levels measured in the investigated population. Analytical precision (SD of four replicate measurements recorded on four different spot depositions of the same sample and automatically measured within the same analytical run) was of 0.9% (0.1% - 4.5%) for samples with HbSSG/HbSH ratios in the range of 3.5% - 11.7%.

### 3.6. Glutathionyl-Haemoglobin Levels in Smokers

Mean HbSSG of the entire group of the 30 investigated subjects is  $6.2\% \pm 1.4\%$  (3.5% - 9.1%), with no apparent difference between genders and no significant statistical correlation with the declared number of cigarettes smoked in the day. However subjects who declared smoking up to 20 cig/day had statistically lower HbSSG levels than those smoking >20 to 40 cig/day ( $5.7\% \pm 1.1\%$  vs.  $7.0\% \pm 1.4\%$ ;  $p < 0.05$ ; **Figure 2**).


HbSSG levels showed no correlation with haemoglobin levels, measured either as concentration (in g/dL) or as haematocrit.

### 3.7. Glutathionyl-Haemoglobin Levels in Overweight-Obese Subjects

Mean HbSSG of the entire group of 20 investigated subjects is  $3.0\% \pm 0.8\%$  (1.9% - 4.6%), with no apparent difference between genders and no significant statistical correlation with the BMI calculated from height and weight recorded at the time of first presentation to the outpatient clinic. HbSSG levels showed no correlation with haemoglobin levels, measured either as concentration (in g/dL) or as haematocrit.

## 4. Discussion and Conclusions

To carry large studies on oxidative stress which involve the measurement of glutathionyl-haemoglobin in human red blood cells, a method that uses MALDI-ToF mass spectrometry is set up and the main factors of analytical variability are studied. By fine-tuning sample depo-



**Figure 1.** MALDI-ToF mass spectra of 1:100 haemolysates of human subjects (for measurement conditions, see Experimental).

sition on the MALDI target and ionization and detection conditions, analytical precision reached 0.9% (0.1% - 4.5%) for samples with HbSSG/HbSH ratios in the range of 3.5% - 11.7% and sensitivity allowed to detect a fraction of HbSSG as low as 0.5%. The stability of HbSSG in red blood cells demonstrated to be sufficiently high for all our study purposes. Neither generation of HbSSG by autoxidation of RBC content, nor its degradation occurred even in not-so-strict sample preparation and storage conditions, in order that only standard separation and washing of RBC was necessary. Further confirmation of this observation comes from a contemporary running study where the stability of red blood cell concentrates

for human transfusion is tested by measuring HbSSG on the day of blood donation and after 42 days of storage at +4°C [27] (Carpani *et al.*, 2011).

To better frame within the body of existing data the results from our investigated population of otherwise healthy subjects, the literature data which have been collected in **Table 1** have been used to generate the histogram of **Figure 3**. Bars show the variability (min-Max) of the levels of HbSSG measured for different examined subpopulations (healthy or control groups of clinical studies; subjects with different conditions or diseases), including those of this study.

The levels measured in our study of otherwise healthy




Figure 2. Levels of glutathionyl haemoglobin in smoking subjects with different self-assessed mean daily cigarette consumption.




Figure 3. Comparison of HbSSG levels measured in the literature studies (interval as determined by the reported results of Table 1). The Country where the studies were performed are reported in the horizontal axis.

groups of heavy smokers and of obese subjects are best compared with those measured in the general Italian population by Biroccio *et al.* [14]. The mean values measured in our subjects place in the upper 3% of the investigated group (two-thirds of the population <0.5%; 10<sup>th</sup> - 90<sup>th</sup> percentile of the remaining 1.6% - 5.2%). It is also apparent that the values measured in the Italian population are much lower than those reported as belonging to the “control groups” of the several studies performed in Indian and Far-Eastern populations.

The values measured are also lower than those measured in dialyzed (5% - 20%; weighted mean 11.4%) [13, 18] and diabetic (5% - 11%; weighted mean 8.3%) [16, 17,20] subjects and, for the group of smokers, approximately in the same range (7.2% ± 2.8%) of healthy subjects who are occupationally exposed to butadiene in chemical plants at airborne concentrations in the range 0.1 - 200 µg/m<sup>3</sup> [19].

To the best of our knowledge, this is the first study measuring HbSSG in a group of otherwise healthy subjects such as heavy smokers and obese, showing that these subjects have higher levels than those reported by others in a healthy population [14]. In particular, the effect of heavy tobacco smoking in generating systemic oxidative stress as measured by glutathionyl haemoglobin is similar to that of a health-threatening degenerative disease such as diabetes and only two-fold less than that experienced by kidney patients undergoing life-saving haemo- or peritoneal dialysis. Glutathionyl-haemoglobin thus shows the effect of oxidative stress associated to tobacco smoking, and it is likely that this innovative biomarker may be useful to assess the extent of damage caused by the harmful effects of tobacco addiction and to monitor the health improvement associated to smoke cessation interventions. As for the effect on oxidative stress of overweight and treatment-refractory obesity, a low yet fairly constant level of HbSSG may strengthen the hypothesis that atherosclerotic plaque is itself a producer of diffusible oxidant species [6] which are able to cross the erythrocyte membrane and oxidize the red blood cell thiolome [28], thus causing the production of disulfide and mixed disulfide species.

## 5. Acknowledgements

We are grateful to the Director and Staff of the Centro Interdipartimentale Grandi Apparecchiature (CIGA) of Università degli Studi di Milano for access to the Bruker Autoflex III MALDI mass spectrometer. The assistance of Marco Pitton, BSc, in performing measurements and data analysis is gratefully acknowledged.

## REFERENCES

- [1] D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling and E. F. M. Wouters, “Systemic Effects of Smoking,” *Chest*, Vol. 131, No. 5, 2007, pp. 1557-1566. [doi:10.1378/chest.06-2179](https://doi.org/10.1378/chest.06-2179)
- [2] L. F. Van Gall, I. L. Mertens and C. E. De Block, “Mechanisms Linking Obesity with Cardiovascular Disease,” *Nature*, Vol. 444, 2006, pp. 875-880. [doi:10.1038/nature05487](https://doi.org/10.1038/nature05487)
- [3] C. Vassalle, C. Novembrino, S. Maffei, *et al.*, “Determinants of Oxidative Stress Related to Gender: Relevance of Age and Smoking Habit,” *Clinical Chemistry and Laboratory Medicine*, Vol. 49, 2011, pp. 1509-1513. [doi:10.1515/CCLM.2011.622](https://doi.org/10.1515/CCLM.2011.622)
- [4] L. Vigna, C. Novembrino, R. De Giuseppe, *et al.*, “Nutritional and Oxidative Status in Occupational Obese Subjects,” *Mediterranean Journal of Nutrition and Metabolism*, Vol. 4, No. 1, 2010, pp. 69-74. [doi:10.1007/s12349-010-0003-1](https://doi.org/10.1007/s12349-010-0003-1)
- [5] C. Vassalle, L. Vigna, S. Bianchi, *et al.*, “A Biomarker of Oxidative Stress as Non-Traditional Risk Factor in Obese Subjects,” *Biomarkers in Nutrition*, Vol. 7, No. 4, 2013, pp. 633-639. [doi:10.2217/bmm.13.49](https://doi.org/10.2217/bmm.13.49)
- [6] M. J. Moller, Z. Qin and B. Toursarkissian, “Tissue Markers in Human Atherosclerotic Carotid Artery Plaque,” *Annals of Vascular Surgery*, Vol. 26, No. 8, 2012, pp. 1160-1165. [doi:10.1016/j.avsg.2012.06.008](https://doi.org/10.1016/j.avsg.2012.06.008)
- [7] S. E. Moriarty, J. H. Shah, M. Lynn, *et al.*, “Oxidation of Glutathione and Cysteine in Human Plasma Associated with Smoking,” *Free Radical Biology and Medicine*, Vol. 35, No. 12, 2003, pp. 1582-1588. [doi:10.1016/j.freeradbiomed.2003.09.006](https://doi.org/10.1016/j.freeradbiomed.2003.09.006)
- [8] M. C. Garel, C. Domenget, J. Caburi-Martin, C. Prehu, F. Galacteros and Y. Beuzard, “Covalent Binding of Glutathione to Haemoglobin. I. Inhibition of Haemoglobin S Polymerization,” *Journal of Biological Chemistry*, Vol. 261, No. 31, 1986, pp. 14704-14709.
- [9] L. Regazzoni, A. Panusa, K.-J. Yeum, M. Carini and G. Aldini, “Haemoglobin Glutathionylation Can Occur through Cysteine Sulfenic Acid Intermediate: Electrospray Ionization LTQ-Orbitrap Hybrid Mass Spectrometry Studies,” *Journal of Chromatography B*, Vol. 877, No. 28, 2009, pp. 3456-3461. [doi:10.1016/j.jchromb.2009.05.020](https://doi.org/10.1016/j.jchromb.2009.05.020)
- [10] S.-E. Bursell and G. L. King, “The Potential Use of Glutathionyl Haemoglobin as a Clinical Marker of Oxidative Stress,” *Clinical Chemistry*, Vol. 46, No. 2, 2000, pp. 145-146.
- [11] K. Murakami and S. Mawatari, “Oxidation of Haemoglobin to Methaemoglobin in Intact Erythrocyte by a Hydroperoxide Induces Formation of Glutathionyl Haemoglobin and Binding of Alpha-Haemoglobin to Membrane,” *Archives of Biochemistry and Biophysics*, Vol. 417, No. 2, 2003, pp. 244-250. [doi:10.1016/S0003-9861\(03\)00389-8](https://doi.org/10.1016/S0003-9861(03)00389-8)
- [12] A. Pastore, A. F. Mozzi, G. Tozzi, L. M. Gaeta, G. Federici, E. Bertini, A. Lo Russo, L. Mannucci and F. Piemonte, “Determination of Glutathionyl-Haemoglobin in Human Erythrocytes by Cation-Exchange High-Performance Liquid Chromatography,” *Analytical Biochemistry*, Vol. 312, No. 2, 2003, pp. 85-90. [doi:10.1016/S0003-2697\(02\)00500-6](https://doi.org/10.1016/S0003-2697(02)00500-6)
- [13] C. Naito, K. Kajita and T. Niwa, “Determination of Glu-

- tathionyl Haemoglobin in Hemodialysis Patients Using Electrospray Ionization Liquid Chromatography-Mass Spectrometry,” *Journal of Chromatography B*, Vol. 731, No. 1, 1999, pp. 121-124.  
[doi:10.1016/S0378-4347\(99\)00139-5](https://doi.org/10.1016/S0378-4347(99)00139-5)
- [14] A. Biroccio, A. Urbani, R. Massoud, C. di Ilio, P. Sacchetta, S. Bernardini, C. Cortese and G. Federici, “A Quantitative Method for the Analysis of Glycated and Glutathionylated Haemoglobin by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry,” *Analytical Biochemistry*, Vol. 336, No. 2, 2005, pp. 279-288. [doi:10.1016/j.ab.2004.10.002](https://doi.org/10.1016/j.ab.2004.10.002)
- [15] F. Piemonte, A. Pastore, G. Tozzi, D. Tagliacozzi, F. M. Santorelli, R. Carozzo, C. Casali, M. Damiano, G. Federici and E. Bertini, “Glutathione in Blood of Patients with Friedreich’s Ataxia,” *European Journal of Clinical Investigation*, Vol. 31, 2001, pp. 1007-1011.  
[doi:10.1046/j.1365-2362.2001.00922.x](https://doi.org/10.1046/j.1365-2362.2001.00922.x)
- [16] Y. Al-Abed, S. VanPatten, H. Li, J. A. Lawson, G. A. FitzGerald, K. R. Manogue and R. Bucala, “Characterization of a Novel Haemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients,” *Molecular Medicine*, Vol. 7, No. 9, 2001, pp. 619-923.
- [17] R. Sampathkumar, M. Balasubramanyam, S. Sudarshani, M. Rema, V. Mohan and P. Balaram, “Increased Glutathionylated Haemoglobin (HbSSG) in Type 2 Diabetes Subjects with Microangiopathy,” *Clinical Biochemistry*, Vol. 38, No. 10, 2005, pp. 892-899.  
[doi:10.1016/j.clinbiochem.2005.06.009](https://doi.org/10.1016/j.clinbiochem.2005.06.009)
- [18] A. K. Mandal, M. Woodi, V. Sood, P. R. Krishnaswamy, A. Rao, S. Ballal and P. Balaram, “Quantitation and Characterization of Glutathionyl Haemoglobin as an Oxidative Stress Marker in Chronic Renal Failure by Mass Spectrometry,” *Clinical Biochemistry*, Vol. 40, No. 13-14, 2007, pp. 986-994.  
[doi:10.1016/j.clinbiochem.2007.05.006](https://doi.org/10.1016/j.clinbiochem.2007.05.006)
- [19] A. Primavera, S. Fustinoni, A. Biroccio, S. Ballerini, A. Urbani, S. Bernardini, G. Federici, E. Capucci, M. Manno and M. Lo Bello, “Glutathione Transferases and Glutathionylated Haemoglobin in Workers Exposed to Low Doses of 1,3-Butadiene,” *Cancer Epidemiology, Biomarkers & Prevention*, Vol. 17, No. 11, 2008, pp. 3004-3012.  
[doi:10.1158/1055-9965.EPI-08-0443](https://doi.org/10.1158/1055-9965.EPI-08-0443)
- [20] C. Naito and T. Niwa, “Analysis of Glutathionyl Haemoglobin Levels in Diabetic Patients by Electrospray Ionization Liquid Chromatography-Mass Spectrometry: Effect of Vitamin E Administration,” *Journal of Chromatography B: Biomedical Sciences and Applications*, Vol. 746, No. 1, 2000, pp. 91-94.  
[doi:10.1016/S0378-4347\(00\)00121-3](https://doi.org/10.1016/S0378-4347(00)00121-3)
- [21] T. Niwa, C. Naito, A. H. Mawjood and K. Imai, “Increased Glutathionyl Haemoglobin in Diabetes Mellitus and Hyperlipidemia Demonstrated by Liquid Chromatography/Electrospray Ionization-Mass Spectrometry,” *Clinical Biochemistry*, Vol. 46, No. 1, 2000, pp. 82-88.
- [22] V. Niketic, D. Beslo, S. Raicevic, S. Sredic and M. Stojkovic, “Glutathione Adduct of Haemoglobin (Hb ASSG) in Hemolysates of Patients on long-Term Antiepileptic Therapy,” *International Journal of Biochemistry*, Vol. 24, No. 3, 1992, pp. 503-507.  
[doi:10.1016/0020-711X\(92\)90046-4](https://doi.org/10.1016/0020-711X(92)90046-4)
- [23] S. Ghilardi, F. M. Rubino, M. Pitton, N. Massetto, M. Bissi, P. Bianciardi, M. Samaja and S. Carelli, “Glutathionyl-Haemoglobin Levels in Carotid Endarterectomy: A Pilot Study on 12 Cases Clinically Uneventful,” *The Journal of Cardiovascular Surgery (Torino)*, 2013, in Press.
- [24] C. Novembrino, G. Cighetti, R. De Giuseppe, L. Vigna, F. de Liso, M. Pellegatta, D. Gregori, R. Maiavacca and F. Bamonti, “Effects of Encapsulated Fruit and Vegetable Juice Powder Concentrates on Oxidative Status in Heavy Smokers,” *Journal of the American College of Nutrition*, Vol. 30, No. 1, 2011, pp. 49-56.  
[doi:10.1080/07315724.2011.10719943](https://doi.org/10.1080/07315724.2011.10719943)
- [25] F. Bamonti, M. Pellegatta, C. Novembrino, L. Vigna, R. De Giuseppe, F. de Liso, D. Gregori, C. Della Noce, L. Patrini, G. Schiraldi, P. Bonara, L. Calvelli, R. Maiavacca and G. Cighetti, “An Encapsulated Juice Powder Concentrate Improves Markers of Pulmonary Function and Cardiovascular Risk Factors in Heavy Smokers,” *Journal of the American College of Nutrition*, Vol. 32, No. 1, 2013, pp. 18-25. [doi:10.1080/07315724.2013.767652](https://doi.org/10.1080/07315724.2013.767652)
- [26] World Health Organization (WHO), “Global Database on Body Mass Index,” 1995.  
[http://apps.who.int/bmi/index.jsp?introPage=intro\\_3.html](http://apps.who.int/bmi/index.jsp?introPage=intro_3.html)
- [27] G. Carpani, S. Ferrari, F. M. Rubino, M. Pitton, M. Pugliano and E. Caneva, “Beta-Glutathionyl-Haemoglobin as a Biomarker of Oxidative Stress: Its Measurement in Red Cell Concentrates. Vox Sanguinis,” *Abstracts of the 21<sup>st</sup> Regional Congress of the ISBT*, Lisbon, 18-22 June 2011, p. 105.
- [28] G. Colombo, I. Dalle-Donne, D. Giustarini, N. Gagliano, N. Portinaro, R. Colombo, R. Rossi and A. Milzani, “Cellular Redox Potential and Haemoglobin S-Glutathionylation in Human and Rat Erythrocytes: A Comparative Study,” *Blood Cells, Molecules, and Diseases*, Vol. 44, No. 3, 2010, pp. 133-139.  
[doi:10.1016/j.bcmd.2009.11.005](https://doi.org/10.1016/j.bcmd.2009.11.005)